Identification of new possible targets for leukemia treatment by kinase activity profiling

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 122-130

  Ter Elst, Arja ^a   Diks, Sander H ^a   Kampen, Kim R ^a   Hoogerbrugge, Peter M ^b   Ruijtenbeek, Rob ^c   Boender, Piet J ^c   Sikkema, Arend H ^a   Scherpen, Frank J G ^a   Kamps, Willem A ^a   Peppelenbosch, Maikel P ^a   De Bont, Eveline S J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PamGene International BV   (Netherlands)

Author keywords

Leukemia; MST1R; signaling pathways; target discovery; Tyrosine kinase activity profiling

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MACROPHAGE ACTIVATING FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ARTICLE; CELL SURVIVAL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; HUMAN CELL; LEUKEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LEUKEMIA; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTOR, TRKB; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 78651294572     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.535181     Document Type: Article

References (27)

1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelo-genous leukemia. N Engl J Med 2002;346:645-652. (Pubitemid 34815868)
2. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108:2358-2365.
3. Tyner JW, Walters DK, Willis SG, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008;111:2238-2245.
4. Lemeer S, Ruijtenbeek R, Pinkse MW, et al. Endogenous phosphotyrosine signaling in zebrafish embryos. Mol Cell Proteomics 2007;6:2088-2099.
5. Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous expression of interleukin-1 beta and inter-leukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. Leukemia 1995;9:425-432.
6. Sikkema AH, Diks SH, den Dunnen WF, et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 2009;69:5987-5995.
7. Hilhorst R, Houkes L, van den BA, Ruijtenbeek R. Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal Biochem 2009;387:150-161.
8. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000;96:2879-2886.
9. Diks SH, Parikh K, van der SM, et al. Evidence for a minimal eukaryotic phosphoproteome? PLoS ONE 2007;2:e777.
10. Foss B, Ulvestad E, Bruserud O. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 2001; 67:267-278.
11. Tsai LH, White L, Raines E, et al. Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines. Blood 1994;83:51-55.
12. Hiwatari M, Ono R, Taki T, et al. Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23). Leukemia 2008;22:2279-2280.
13. Li Z, Beutel G, Rhein M, et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 2009;113:2028-2037.
14. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108:2358-2365.
15. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-859.
16. Kim SC, Hahn JS, Min YH, et al. Constitutive activation of extracellular signal-regulated kinase in human acute leuke-mias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 1999;93:3893-3899.
17. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94:3707-3716.
18. Kerr AH, James JA, Smith MA, et al. An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia. Ann NY Acad Sci 2003;1010:86-89.
19. James JA, Smith MA, Court EL, et al. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J 2003;4:427-432.
20. Stegmaier K, Corsello SM, Ross KN, et al. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005;106:2841-2848.
21. Boehrer S, Ades L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008;111:2170-2180.
22. Lindhagen E, Eriksson A, Wickstrom M, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008;81:344-353.
23. Spengeman JD, Green TD, McCubrey JA, Bertrand FE. Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle 2005;4:483-487.
24. Wang MH, Yao HP, Zhou YQ. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 2006;27:641-650.
25. Bardella C, Costa B, Maggiora P, et al. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 2004;64:5154-5161.
26. Angeloni D, Nilkovitch-Miagkova A, Ivanova T, et al. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 2007;26:4499-4512.
27. Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010;16:1973-1978.